Immune checkpoint inhibitor therapy for malignant melanoma / 中华皮肤科杂志

ABSTRACT

Immune checkpoint inhibitors (ICIs) have become an important treatment option for many patients with malignant melanoma in the past few years. ICIs can restore and promote the function of effector T cells to specifically recognize and kill tumor cells, and systemically enhance anti-tumor immune response of the body, so they are a good treatment option for patients who have a high risk of recurrence after surgery or are at an advanced stage of disease (unresectable or metastatic melanoma). The main targets of current ICIs are programmed cell death-1 receptor and cytotoxic T lymphocyte-associated antigen 4, which are two key receptors for central and peripheral immune tolerance respectively. This review mainly discusses clinical efficacy of different ICIs, potential biomarkers for predicting response to ICIs and ICI-related adverse reactions.